The University of Chicago Header Logo

Connection

Daniel Shevrin to Aged

Back to Details
This is a "connection" page, showing publications Daniel Shevrin has written about Aged.
Daniel Shevrin
Connection Strength
0.206
Aged
  1. An item bank was created to improve the measurement of cancer-related fatigue. J Clin Epidemiol. 2005 Feb; 58(2):190-7.
    View in: PubMed
    Score: 0.019
  2. Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI). Health Qual Life Outcomes. 2003 Nov 21; 1:69.
    View in: PubMed
    Score: 0.018
  3. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 06; 114:107-116.
    View in: PubMed
    Score: 0.013
  4. Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. Future Oncol. 2018 Mar; 14(6):527-536.
    View in: PubMed
    Score: 0.012
  5. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018 04 01; 36(10):991-999.
    View in: PubMed
    Score: 0.012
  6. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 02 01; 36(4):376-382.
    View in: PubMed
    Score: 0.012
  7. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017 05; 71(5):740-747.
    View in: PubMed
    Score: 0.011
  8. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. Urology. 2015 Dec; 86(6):1206-11.
    View in: PubMed
    Score: 0.010
  9. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20; 373(8):737-46.
    View in: PubMed
    Score: 0.010
  10. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44.
    View in: PubMed
    Score: 0.009
  11. Phase II trial of 6-thioguanine in advanced renal cell carcinoma. An Illinois Cancer Center study. Invest New Drugs. 1994; 12(4):345-6.
    View in: PubMed
    Score: 0.009
  12. Phase II trial of echinomycin in advanced hormone-resistant prostate cancer. An Illinois Cancer Council study. Invest New Drugs. 1994; 12(1):65-6.
    View in: PubMed
    Score: 0.009
  13. Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urol Oncol. 2014 Jan; 32(1):26.e25-31.
    View in: PubMed
    Score: 0.009
  14. Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index. Psychooncology. 2011 Sep; 20(9):977-83.
    View in: PubMed
    Score: 0.007
  15. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health. 2010 Aug; 13(5):613-23.
    View in: PubMed
    Score: 0.007
  16. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study. Invest New Drugs. 1989 Jul; 7(2-3):251-3.
    View in: PubMed
    Score: 0.007
  17. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2437-43.
    View in: PubMed
    Score: 0.006
  18. Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage. 2008 Jan; 35(1):20-30.
    View in: PubMed
    Score: 0.006
  19. Longitudinal screening and management of fatigue, pain, and emotional distress associated with cancer therapy. Support Care Cancer. 2008 Feb; 16(2):151-9.
    View in: PubMed
    Score: 0.006
  20. Phase II trial of aminothiadiazole in advanced non-small cell lung cancer. Cancer Treat Rep. 1986 Mar; 70(3):417-8.
    View in: PubMed
    Score: 0.005
  21. Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):221-6.
    View in: PubMed
    Score: 0.004
  22. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000 Aug; 23(4):371-5.
    View in: PubMed
    Score: 0.004
  23. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer. 1993 Sep 15; 72(6):1965-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.